Literature DB >> 3147136

Pharmacoangiographic assessment of the corpora cavernosa.

J J Bookstein1, B Fellmeth, S Moreland, A L Lurie.   

Abstract

The present section presents further observations regarding cavernosometry and cavernosography, emphasizing the value of intracavernosal injection of a papaverine-phentolamine combination. Subsequent pharmacocavernosometry during fluid infusion then enables (1) precise quantitation of cavernosal leak by the pharmacologic maintenance erection flow (PMEF) method, and (2) determination of cavernosal pressure pulsations, a useful reflection of arterial sufficiency. In patients with excessive cavernosal leak, pharmacocavernosography supplements the examination by indicating the routes of persistent major venous drainage, key information in planning venoablative therapy. Compared with nonpharmacologic methods for cavernosometry and cavernosography, we feel the pharmacologic technique offers the following advantages: (1) it enables the highly accurate and reproducible PMEF method for quantitating cavernosal leakage; (2) the sites of abnormal leakage can be evaluated by cavernosography only after the pharmacologic technique; (3) the infusion volumes required to produce erection are smaller, more physiologic, and more conveniently administered; (4) the amplitude of the cavernosal pressure pulsation becomes useful as an index of arterial sufficiency; and (5) pulsations of the dorsal penile artery are amplified to the point of easy palpability, or more reliable Doppler detection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147136     DOI: 10.1007/bf02577006

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  11 in total

1.  Dynamic corpus cavernosography: effect of papaverine injection.

Authors:  F A Puyau; R W Lewis; P Balkin; M B Kaack; A Hirsch
Journal:  Radiology       Date:  1987-07       Impact factor: 11.105

2.  Physiology of erection and pharmacological management of impotence.

Authors:  T F Lue; E A Tanagho
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450

3.  Techniques for performing cavernosometry and cavernosography.

Authors:  C Delcour; J Struyven
Journal:  Cardiovasc Intervent Radiol       Date:  1988-08       Impact factor: 2.740

4.  Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration.

Authors:  G R Fournier; K P Juenemann; T F Lue; E A Tanagho
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

5.  Corpus cavernosography. Pressure flow and radiography.

Authors:  F A Puyau; R W Lewis
Journal:  Invest Radiol       Date:  1983 Nov-Dec       Impact factor: 6.016

6.  Penile pharmacocavernosography and cavernosometry in the evaluation of impotence.

Authors:  J J Bookstein; K Valji; L Parsons; W Kessler
Journal:  J Urol       Date:  1987-04       Impact factor: 7.450

7.  Cavernosal venocclusive insufficiency in male impotence: evaluation of degree and location.

Authors:  J J Bookstein
Journal:  Radiology       Date:  1987-07       Impact factor: 11.105

8.  Angiography of posttraumatic impotence.

Authors:  A L Lurie; J J Bookstein; W O Kessler
Journal:  Cardiovasc Intervent Radiol       Date:  1988-08       Impact factor: 2.740

9.  Transluminal penile venoablation for impotence: a progress report.

Authors:  J J Bookstein; A L Lurie
Journal:  Cardiovasc Intervent Radiol       Date:  1988-08       Impact factor: 2.740

10.  Cavernometry-cavernography: its role in organic impotence.

Authors:  E Wespes; C Delcour; J Struyven; C C Schulman
Journal:  Eur Urol       Date:  1984       Impact factor: 20.096

View more
  2 in total

Review 1.  Bicycle riding, perineal trauma, and erectile dysfunction: data and solutions.

Authors:  Irwin Goldstein; Alan L Lurie; John P Lubisich
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

2.  Transluminal penile venoablation for impotence: a progress report.

Authors:  J J Bookstein; A L Lurie
Journal:  Cardiovasc Intervent Radiol       Date:  1988-08       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.